CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
I 124-Evuzamitidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05635045
NCT05635045Phase 2Completed
CompareCT.gov

A Follow-Up Study to Monitor Therapeutic Response in Transthyretin Cardiac Amyloidosis Using Amyloid Reactive Peptide 124I-evuzamitide (AT01) PET/CT

Columbia University·interventional·Posted Dec 2, 2022·Updated Jul 18, 2025

In Brief

A Phase 2 clinical trial evaluating I 124-Evuzamitide for Transthyretin Amyloidosis. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan. Ten previously scanned subjects re-consented to undergo another 124I-evuzamitide PET scan. Demographic, clinical and phenotypic data were collected to characterize potential changes since their previous scans.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransthyretin Amyloidosis
CountriesUnited States
CollaboratorsAttralus, Inc.

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedDec 2, 2022
Enrollment StartJul 8, 2022
Primary CompletionMay 7, 2024
Study CompletionJun 12, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 3.6 years ago

Interventions

I 124-Evuzamitidedrug

Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging